Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
Crossref DOI link: https://doi.org/10.1007/s40268-015-0100-1
Published Online: 2015-08-19
Published Print: 2015-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ruof, Jörg
Flückiger, Olivier
Andre, Niko
License valid from 2015-08-19